Skip to main content
NYSE:ZTS

Zoetis Stock Forecast, Price & News

$171.54
+0.69 (+0.40 %)
(As of 05/14/2021 10:02 AM ET)
Add
Compare
Today's Range
$170.95
$172.32
50-Day Range
$152.88
$175.24
52-Week Range
$121.50
$176.64
Volume3,267 shs
Average Volume1.99 million shs
Market Capitalization$81.44 billion
P/E Ratio50.90
Dividend Yield0.60%
Beta0.71
30 days | 90 days | 365 days | Advanced Chart
Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.


Zoetis logo

About Zoetis

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000
Employees11,300
Year Founded2012

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.88 per share
Book Value$5.69 per share

Profitability

Net Income$1.50 billion

Debt

Price-To-Earnings

Miscellaneous

Market Cap$81.44 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Social Links


MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

155th out of 2,038 stocks

Pharmaceutical Preparations Industry

61st out of 769 stocks

Analyst Opinion: 1.3Community Rank: 3.2Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zoetis (NYSE:ZTS) Frequently Asked Questions

Is Zoetis a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zoetis stock.
View analyst ratings for Zoetis
or view top-rated stocks.

What stocks does MarketBeat like better than Zoetis?

Wall Street analysts have given Zoetis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zoetis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,690,000 shares, an increase of 29.6% from the March 15th total of 3,620,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.0% of the company's stock are short sold.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Zoetis
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings results on Thursday, May, 6th. The company reported $1.26 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.04 by $0.22. The firm earned $1.87 billion during the quarter, compared to the consensus estimate of $1.73 billion. Zoetis had a trailing twelve-month return on equity of 63.89% and a net margin of 25.50%. The business's quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the company posted $0.95 EPS.
View Zoetis' earnings history
.

How has Zoetis' stock been impacted by COVID-19 (Coronavirus)?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZTS shares have increased by 31.2% and is now trading at $170.85.
View which stocks have been most impacted by COVID-19
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Wednesday, February 10th. Shareholders of record on Wednesday, April 21st will be given a dividend of $0.25 per share on Tuesday, June 1st. This represents a $1.00 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Tuesday, April 20th.
View Zoetis' dividend history
.

Is Zoetis a good dividend stock?

Zoetis pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.60%. Zoetis does not yet have a strock track record of dividend growth. The dividend payout ratio of Zoetis is 27.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 24.27% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share (EPS) guidance of 4.420-4.510 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.450. The company issued revenue guidance of $7.50 billion-$7.63 billion, compared to the consensus revenue estimate of $7.47 billion.

What price target have analysts set for ZTS?

15 brokerages have issued 12 month price objectives for Zoetis' stock. Their forecasts range from $152.00 to $208.00. On average, they anticipate Zoetis' stock price to reach $180.67 in the next twelve months. This suggests a possible upside of 5.7% from the stock's current price.
View analysts' price targets for Zoetis
or view top-rated stocks among Wall Street analysts.

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Ms. Kristin C. Peck, CEO & Director (Age 50, Pay $2.79M) (LinkedIn Profile)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 49, Pay $1.53M) (LinkedIn Profile)
  • Ms. Wafaa Mamilli, Exec. VP and Chief Information & Digital Officer (Age 54, Pay $2.6M) (LinkedIn Profile)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 60, Pay $1.51M) (LinkedIn Profile)
  • Mr. Roman Trawicki, Exec. VP and Pres of Global Manufacturing & Supply (Age 57, Pay $2.19M) (LinkedIn Profile)
  • Ms. Roxanne Lagano, Exec. VP and Chief HR Officer & Global Operations (Age 56) (LinkedIn Profile)
  • Mr. Steven Frank, VP of Investor Relations
  • Ms. Heidi C. Chen, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54) (LinkedIn Profile)
  • Mr. William Price, VP & Chief Communications Officer
  • Mr. Timothy J. Bettington, Exec. VP & Pres of U.S. Operations (Age 47) (LinkedIn Profile)

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among Zoetis' employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.31%), Alliancebernstein L.P. (3.75%), Polen Capital Management LLC (2.44%), Clearbridge Investments LLC (1.72%), Geode Capital Management LLC (1.60%) and Northern Trust Corp (1.23%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis
.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, BlackRock Inc., Jennison Associates LLC, Massachusetts Financial Services Co. MA, The Manufacturers Life Insurance Company, Cantillon Capital Management LLC, Lord Abbett & CO. LLC, and Clearbridge Investments LLC. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis
or view top insider-selling stocks.

Which major investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Toronto Dominion Bank, Renaissance Technologies LLC, Principal Financial Group Inc., UBS Asset Management Americas Inc., GSB Wealth Management LLC, Credit Suisse AG, and Fayez Sarofim & Co.
View insider buying and selling activity for Zoetis
or or view top insider-buying stocks.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $170.85.

How much money does Zoetis make?

Zoetis has a market capitalization of $81.11 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis.

How many employees does Zoetis have?

Zoetis employs 11,300 workers across the globe.

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..

When was Zoetis founded?

Zoetis was founded in 2012.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

Where are Zoetis' headquarters?

Zoetis is headquartered at 10 Sylvan Way, Parsippany NJ, 07054.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.